Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA workshop on ANDA deficiencies

Executive Summary

Scheduled for Sept. 24 at the Parklawn Building conference rooms D & E to provide guidance to industry on improving ANDAs. FDA will present preliminary results of study by Evaluation and Analysis staff on chemistry and manufacturing deficiencies found in ANDA submissions. According to Staff Director Douglas Sporn, FDA evaluated a random sample of ANDAs that generated at least two deficiency letters. A total of 1,200 deficiencies, including chemistry, manufacturing and labeling, were found in the 45 ANDAs selected. The completed study may be released before the end of October. The workshop will also include discussion on the Office of Generic Drugs Policy and Procedure Guides.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts